This observational study examined whether central pain sensitivity is associated with fatigue in RA and whether such associations are explained by pain severity or inflammation.

This study examines sex differences in the initiation and retention rate of biological disease-modifying antirheumatic drugs (bDMARDs) among patients with spondyloarthritis (SpA) over a 17-year follow-up period, and identifies sex-specific predictors of these treatment outcomes.

In a cross-sectional study, we aimed at characterizing possible impairments in sleep health and rest-activity parameters between patients with Sjögren's Disease (SjD) and healthy controls (HCs). Furthermore, we explored possible predictors of such disturbances in the SjD group.

The heterogeneous presentation of axial SpA (axSpA) complicates diagnosis and treatment decisions. This study compared patient symptoms, health-care resource utilization, and physician-patient alignment on disease severity and treatment satisfaction between the USA and five European countries (5EU).

Rheumatoid arthritis (RA) has been associated with substantial work loss, but advances in treatment have improved clinical outcomes for patients over time calling for an updated assessment. We therefore aimed to examine calendar trends in the association between RA diagnosis and work loss.

Early and accurate detection of inflammatory activity is essential in inflammatory arthropathies, as timely treatment can prevent irreversible joint damage. Optical spectral transmission (OST), implemented in the HandScan device, is a novel, non-invasive imaging method that uses red and near-infrared light to detect perfusion changes associated with angiogenesis and hypervascularity in inflamed joints. This review summarizes current evidence on OST, assessing its diagnostic performance and clinical utility relative to musculoskeletal ultrasound, magnetic resonance imaging, and conventional clinical activity indices.

Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerability and clinical efficacy in patients with psoriatic arthritis (PsA). Here, we report an additional year of safety and efficacy of bimekizumab to 3 years.

We aimed to investigate the influence of anti-SSA/Ro antibodies and other factors on adverse pregnancy outcomes (APOs) in systemic lupus erythematosus (SLE) patients.

SSc is characterized by micro- and macrovascular damage, increasing cardiovascular (CV) risk. The SCORE2 algorithm underestimates CV risk in systemic autoimmune diseases. Nailfold capillaroscopy (NFC) is used to assess SSc-related microvascular damage. We aimed to evaluate whether incorporating NFC findings into SCORE2/SCORE2-OP improves CV risk stratification in SSc.

To quantify the longitudinal association between radiographic spinal damage and spinal mobility and physical function in radiographic axial SpA (r-axSpA) using disco-vertebral unit (DVU)-level analyses.

To present a successful case study of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in a patient with relapsing granulomatosis with polyangiitis (GPA).

To evaluate the vaccination attitude and behaviour of patients with autoimmune inflammatory rheumatic diseases (AIIRD), and identify factors associated with vaccination status, utilizing data from a national register.

Belimumab improves outcomes in childhood-onset systemic lupus erythematosus (cSLE) but raises infection risks due to B cell modulation. We aimed to evaluate dynamic B cell and immunoglobulin G (IgG) monitoring for predicting infection risk.

Axial spondyloarthritis (axSpA) diagnoses are often delayed, which is associated with poorer patient outcomes. To improve understanding of diagnostic delay in France, we describe the time and patient journey to axSpA diagnosis in primary care.

MicroRNAs (miRNAs) play critical roles in regulating immune cell differentiation and maintaining innate and adaptive immune homeostasis. The aim of this study was to determine the mechanisms by which miR-23b-3p modulates crosstalk between innate and adaptive immunity in immunoglobulin A (IgA) vasculitis (IgAV) and to evaluate its therapeutic potential.

Most studies on renal outcomes in ANCA-associated vasculitis (AAV) focus on GN; however, the prognosis of patients without clinically apparent kidney involvement is understudied. We aimed to characterize kidney prognosis in this overlooked subgroup.

Juvenile psoriatic arthritis and enthesitis-related arthritis are two categories of juvenile idiopathic arthritis (JIA). Despite available treatments including non-steroidal anti-inflammatory drugs, glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), and biological DMARDs, a substantial proportion of people do not adequately respond to treatment or do not have long-lasting clinical remission. The aim of this trial was to show the efficacy and safety of ixekizumab in children with active enthesitis-related arthritis and juvenile psoriatic arthritis.

The impact of biologic sex in axial juvenile spondyloarthritis (axJSpA) is unknown. We assessed whether biologic sex is associated with disease manifestations, patient-reported outcomes, or characteristic sacroiliac joint (SIJ) MRI lesions in a large cohort of youths with classified axJSpA.

Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting millions of people worldwide. Genetic factors, including specific polymorphisms such as the anti-inflammatory cytokine Interleukin (IL)-37, play a significant role in RA. This meta-analysis and systematic review investigated the associations between IL-37 gene polymorphisms and susceptibility and clinical outcomes of RA.

Neurodevelopmental disorders affect a substantial proportion of children and represent a major public health challenge worldwide. Emerging evidence highlights complex interactions among genetic, environmental and immune factors - particularly during the critical window of neurodevelopmental vulnerability. These insights raise the possibility that children with juvenile systemic autoimmune and autoinflammatory diseases are at an increased risk of developing neurodevelopmental disorders. Early onset and delayed treatment of these autoimmune and autoinflammatory diseases seem to increase this vulnerability. Growing awareness of these associations is transforming paediatric rheumatology, highlighting the need for early screening, multidisciplinary management, and personalized interventions that target both inflammatory disease and neurodevelopment. International research collaborations, biomarker discovery and long-term follow-up are crucial for closing knowledge gaps and subsequently advancing care and outcomes. Recognizing and tackling neurodevelopmental disorders as frequent comorbidities of juvenile systemic autoimmune and autoinflammatory diseases is vital for improving educational attainment, psychosocial wellbeing and lifelong quality of life in children with chronic inflammatory conditions.